Category: Peptide Blends

BPC-157 and TB-500 are two of the most frequently paired names in the research-peptide literature, often listed side by side or offered as a combined preparation. That pairing can make them sound like variations on a single compound. They are not. They are structurally distinct peptides with different origins, different lengths, and different molecular mechanisms — and published research has examined each on its own as well as in combination. This article describes what each one is at the molecular level, where they come from, and why researchers study them as separate compounds.

What BPC-157 is at the molecular level

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids. The name “pentadecapeptide” simply encodes that length (penta-deca = fifteen). Its amino-acid sequence is Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val, and that sequence is the defining fact about the molecule.

BPC-157 was derived from a partial sequence of a protein found in human gastric juice — the body-protection compound (BPC) from which it takes its name. To be precise: BPC-157 is not that whole protein and does not occur as such in the body. It is a synthetic fragment, a defined 15-residue stretch corresponding to a portion of the parent gastric protein, manufactured to a fixed sequence for laboratory use. One characteristic noted across the literature is that this fragment is comparatively stable in the acidic, enzyme-rich environment of gastric juice, which is part of why this specific sequence became a research subject.

What TB-500 is at the molecular level

TB-500 is a much shorter molecule and comes from a completely different parent. It is a synthetic 7-amino-acid peptide corresponding to the actin-binding region of thymosin β-4 (Tβ4), a naturally occurring 43-amino-acid protein present in nearly every cell type. The relevant stretch — the residues LKKTETQ, positions 17 to 23 of thymosin β-4 — is the segment of the parent protein most directly associated with binding to actin.

This is the precision point that matters most: TB-500 is not identical to full-length thymosin β-4. The two names are frequently treated as synonyms, but structurally they are not the same molecule. Thymosin β-4 is the full 43-residue protein; TB-500 is a short synthetic fragment built around its central actin-binding motif. A 7-residue synthetic peptide and a 43-residue protein are distinct chemical entities.

Why they are structurally distinct compounds

Set the two side by side and the differences are immediate:

• Origin — BPC-157 derives from a human gastric-juice protein; TB-500 derives from thymosin β-4, a near-ubiquitous intracellular protein.
• Length — BPC-157 is 15 amino acids; the TB-500 fragment is 7 amino acids.
• Sequence — they share no defining sequence motif; the proline-rich BPC-157 chain and the LKKTETQ actin-binding stretch are unrelated.
• Molecular target — their mechanisms, described below, operate on entirely different molecular systems.

Because the two are chemically unrelated, the literature treats them as separate compounds, characterizing each individually. The “blend” framing — the reason a combined BPC-157 + TB-500 blend exists as a research preparation — reflects interest in studying two distinct mechanisms in the same model system, not a claim that they are one substance or that one is a form of the other.

Different mechanisms: what the published studies measured

The clearest way to see that these are distinct compounds is to look at what published research measured for each, in the research models studied. The mechanisms do not overlap.

BPC-157 and the angiogenesis / VEGFR2 system. In cell and animal models, BPC-157 has been studied in relation to blood-vessel formation. One study reported that, in endothelial cells and in a rat hind-limb model, BPC-157 was associated with up-regulation and internalization of VEGFR2 (vascular endothelial growth factor receptor 2) and activation of the VEGFR2–Akt–eNOS signaling axis, parameters the authors used to characterize angiogenesis in those models (Hsieh et al., J Mol Med (Berl), 2017). A separate study in tendon fibroblasts reported that BPC-157 increased expression of the growth hormone receptor in those cells, measured at the mRNA and protein level (Chang et al., Molecules, 2014). These are the molecular readouts associated with BPC-157 in the cited work.

TB-500 and actin dynamics. The mechanism attributed to TB-500 is entirely different and follows from the parent protein. Thymosin β-4 is an actin-sequestering protein: it binds monomeric G-actin and holds it in a form that is not readily added onto growing actin filaments (F-actin), which is how a cell regulates its pool of available actin. A structural study resolved how thymosin β-4 accomplishes this, describing it as capping both ends of the actin monomer (Irobi et al., EMBO J, 2004). The LKKTETQ region that TB-500 corresponds to sits at the core of this actin interaction. Separate work reported that the actin-binding site of thymosin β-4 was associated with angiogenesis in the assays used (Philp et al., FASEB J, 2003), and earlier research characterized thymosin β-4 in a wound model, where it measured increased cell migration and re-epithelialization relative to controls (Malinda et al., J Invest Dermatol, 1999).

The contrast is the point. The published mechanism for BPC-157 centers on growth-factor receptor signaling (VEGFR2, growth hormone receptor); the mechanism for the thymosin β-4 region that TB-500 represents centers on actin monomer binding and cytoskeletal dynamics. Two different molecular systems, two structurally different peptides.

Frequently asked questions

Are BPC-157 and TB-500 the same thing?

No. They are structurally distinct peptides. BPC-157 is a 15-amino-acid synthetic peptide derived from a human gastric-juice protein. TB-500 is a 7-amino-acid synthetic peptide corresponding to the actin-binding region of thymosin β-4. They share no defining sequence and act on different molecular systems.

Is TB-500 the same as thymosin β-4?

Not exactly. Thymosin β-4 is a full-length, naturally occurring 43-amino-acid protein. TB-500 is a short synthetic fragment corresponding to that protein’s central actin-binding region (the LKKTETQ stretch). They overlap in that region but are different chemical entities — a 7-residue peptide is not the same molecule as a 43-residue protein.

What makes BPC-157 a “pentadecapeptide”?

“Pentadecapeptide” means a peptide of 15 amino acids (penta-deca = fifteen). BPC-157 is a defined 15-residue sequence (Gly–Glu–Pro–Pro–Pro–Gly–Lys–Pro–Ala–Asp–Asp–Ala–Gly–Leu–Val), which is what the term describes.

Why are they studied together as a blend?

Because they are two distinct compounds with two distinct published mechanisms, researchers sometimes study them in the same model to characterize both at once. The blend framing reflects interest in two separate molecular systems, not a claim that the two peptides are the same or that one is a form of the other.

What did published studies actually measure for each?

For BPC-157, cited studies measured molecular readouts such as VEGFR2 expression and signaling in endothelial and animal models, and growth hormone receptor expression in tendon fibroblasts. For the thymosin β-4 region that TB-500 corresponds to, cited studies measured actin-monomer binding (sequestration of G-actin) and related cytoskeletal and angiogenesis endpoints in their respective model systems.

Do BPC-157 and TB-500 act on the same target?

No. The mechanism associated with BPC-157 centers on growth-factor receptor signaling, while the mechanism associated with the thymosin β-4 region behind TB-500 centers on binding monomeric actin. These are different molecular targets.

References

1. Chang CH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014. PMID: 25415472.
2. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine. 2017. PMID: 27847966.
3. Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003. PMID: 14500546.
4. Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO Journal. 2004. PMID: 15329672.
5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999. PMID: 10469335.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

The GLOW stack is a three-component research blend that pairs GHK-Cu, BPC-157, and TB-500 in a single vial. The name is an acronym drawn from the components rather than a description of any result, and the three peptides are chemically unrelated to one another — a copper-binding tripeptide, a gastric-derived pentadecapeptide, and an actin-binding peptide fragment. This explainer covers what each molecule actually is at the structural level, and what published research has measured for each in laboratory models. You can see the combined GLOW blend on its product page; this article is about the chemistry behind it.

What the GLOW stack is

“GLOW” is a label applied to a fixed combination of three distinct research peptides supplied together. A blend is simply three separate molecules co-located in one container, each with its own structure, class, and body of literature. The three are:

• GHK-Cu — the copper(II) complex of a naturally occurring tripeptide.
• BPC-157 — a synthetic pentadecapeptide (15 amino acids) whose sequence corresponds to a fragment of a protein identified in gastric juice.
• TB-500 — a synthetic peptide corresponding to the actin-binding region of the protein thymosin β-4.

Because the components are chemically independent, the most accurate way to understand the blend is to understand each molecule on its own terms. The sections below do exactly that, and in each case the physiological language is confined to what cited studies measured in research models rather than any outcome attributed to a person.

GHK-Cu: a copper-binding tripeptide

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine — three amino acids in sequence: glycine, histidine, and lysine (Gly-His-Lys, abbreviated GHK). The histidine residue gives the peptide a strong affinity for copper ions, so in the presence of copper(II) it forms a stable complex; that complexed form is what is written as GHK-Cu. The underlying GHK tripeptide was originally isolated from human plasma, which makes it a naturally occurring sequence rather than a purely designed one.

In the published literature, GHK and its copper complex have been studied as modulators of gene expression and extracellular-matrix turnover. A review of the molecule’s biochemistry catalogued research in cell and tissue models reporting effects on the expression of genes involved in collagen and glycosaminoglycan synthesis and in tissue remodeling (Pickart et al., BioMed Research International, 2015). Those are descriptions of what investigators measured in their experimental systems — the citation is the claim.

BPC-157: a gastric-derived pentadecapeptide

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids. The abbreviation BPC stands for “Body Protection Compound,” and the sequence corresponds to a partial fragment of a larger protein that was identified in human gastric juice. In other words, BPC-157 did not originate as a de novo designed drug; it was derived from a naturally observed protective protein, and the 15-residue fragment that retained activity in early experiments became the compound studied under the BPC-157 name. It is manufactured synthetically and is reported to be stable in gastric juice, a property that distinguishes it from many small peptides that degrade rapidly.

BPC-157 has been characterized almost entirely in animal and cell models. A wide-ranging review by the group that first described the peptide summarized decades of preclinical work positioning it within the framework of gastric cytoprotection (Sikiric et al., Gut and Liver, 2019). A separate study examined the peptide in a rat model of injured myotendinous junctions, reporting measurements relevant to connective-tissue repair in that model (Japjec et al., Biomedicines, 2021). Both citations describe findings in research subjects, not effects in people.

TB-500: an actin-binding peptide fragment

TB-500 is a synthetic peptide corresponding to the actin-binding region of thymosin β-4, a small, naturally abundant protein found in many tissues. Thymosin β-4 itself is a 43-amino-acid polypeptide and is regarded as the principal G-actin–sequestering peptide in cells, meaning it binds monomeric actin and influences the assembly of the actin cytoskeleton. TB-500 reproduces the short, central actin-binding motif of that parent protein rather than the full-length molecule, which is the structural reason it is described as a fragment or analog rather than as thymosin β-4 itself.

Research on thymosin β-4 and its actin-binding motif has been conducted in cell and animal models. One study localized the angiogenic activity of thymosin β-4 to its actin-binding site, reporting that the isolated motif drove endothelial cell migration in assays comparably to the full protein (Philp et al., FASEB Journal, 2003). A broader review described the protein’s role as an actin-sequestering molecule and surveyed tissue-repair–related findings across experimental systems (Goldstein et al., Trends in Molecular Medicine, 2005). Again, these are measurements made in laboratory models.

How GLOW relates to KLOW

GLOW is frequently discussed alongside a closely related four-component blend called KLOW. The relationship is straightforward arithmetic at the level of ingredients: KLOW is GLOW plus one additional peptide, KPV. KPV is a synthetic tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment of the larger α-melanocyte–stimulating hormone (α-MSH) sequence. So the two blends share the same GHK-Cu / BPC-157 / TB-500 base, and the only structural difference is the presence or absence of that fourth tripeptide.

Put simply:

• GLOW = GHK-Cu + BPC-157 + TB-500 (three components).
• KLOW = GHK-Cu + BPC-157 + TB-500 + KPV (four components).

If you want the version that adds the KPV tripeptide, the KLOW blend is the corresponding four-component product. Choosing between them is a question of which set of research molecules a given study design calls for.

Frequently asked questions

What is the GLOW stack made of?

The GLOW stack is a research blend of three distinct peptides: GHK-Cu (a copper-binding tripeptide), BPC-157 (a 15-amino-acid pentadecapeptide), and TB-500 (a fragment corresponding to the actin-binding region of thymosin β-4). They are chemically unrelated molecules supplied together in one vial.

What does GHK-Cu stand for?

GHK-Cu denotes the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. “GHK” is the single-letter shorthand for that glycine–histidine–lysine sequence, and “Cu” is the chemical symbol for copper, which the peptide binds.

What does BPC-157 stand for?

BPC stands for “Body Protection Compound.” BPC-157 is a synthetic pentadecapeptide whose sequence corresponds to a fragment of a protein originally identified in gastric juice.

Is TB-500 the same as thymosin beta-4?

No. Thymosin β-4 is the full 43-amino-acid protein. TB-500 is a synthetic peptide corresponding to its shorter actin-binding motif, so it is a fragment or analog of the parent protein rather than the complete molecule.

What is the difference between GLOW and KLOW?

KLOW is GLOW with one additional peptide. Both contain GHK-Cu, BPC-157, and TB-500; KLOW also includes KPV, a lysine-proline-valine tripeptide derived from the α-MSH sequence.

Are these peptides approved for human use?

No. GHK-Cu, BPC-157, and TB-500 are research compounds studied in laboratory and animal models, and the products discussed here are intended for laboratory research only, not for human or veterinary use.

References

1. Pickart L, et al. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015. PMID: 26236730.
2. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157, Robert’s Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye’s Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020. PMID: 31158953.
3. Japjec M, et al. Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats. Biomedicines. 2021. PMID: 34829776.
4. Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. FASEB Journal. 2003. PMID: 14500546.
5. Goldstein AL, et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PMID: 16099219.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.

The KLOW blend is one of the more frequently searched multi-component research peptides, and the name itself is the source of most of the confusion: KLOW is not a single molecule but an acronym for a fixed combination of four separate research peptides — GHK-Cu, BPC-157, TB-500 and KPV. Each of the four is a distinct chemical entity with its own sequence, its own structural class, and its own body of published literature. This explainer breaks down what each component is at the molecular level and what published studies have actually measured for each one in research models, so the acronym stops being a black box.

What the KLOW acronym stands for

KLOW is a portmanteau built from the names of its four constituents. It is closely related to another blend, GLOW, which combines three of the four: GHK-Cu, BPC-157 and TB-500. KLOW is simply GLOW with the tripeptide KPV added — the leading “K” in the name. So the relationship is straightforward:

• GLOW = GHK-Cu + BPC-157 + TB-500 (three components)
• KLOW = KPV + GHK-Cu + BPC-157 + TB-500 (the GLOW trio plus KPV)

Because each of the four is an independent compound, understanding KLOW means understanding the four molecules individually. None of them is a derivative of another; they belong to different structural families entirely — a copper-bound tripeptide, a synthetic pentadecapeptide, a synthetic actin-binding heptapeptide, and a hormone-derived tripeptide. The combined KLOW blend is sold as a single research preparation, but chemically it is four molecules sharing a vial.

GHK-Cu: the copper tripeptide

GHK-Cu is glycyl-L-histidyl-L-lysine — a three-amino-acid peptide (glycine–histidine–lysine) bound to a copper(II) ion. The “Cu” in the name is that bound copper. GHK was first isolated from human plasma in the 1970s, and the histidine residue gives the tripeptide its characteristic high affinity for copper, forming a stable complex. It is the copper-bound form, GHK-Cu, rather than the bare peptide, that is the species studied in most of the matrix-remodeling literature.

Published research on GHK-Cu has largely centered on connective-tissue and extracellular-matrix biology in cell-culture models. In cultured fibroblasts, one study measured an increase in matrix metalloproteinase-2 (MMP-2) expression in the presence of the GHK-Cu complex, an effect the authors attributed to the copper component (Siméon et al., Life Sciences, 2000). This is the kind of measurement that defines GHK-Cu in the literature: a molecule studied for how it modulates the proteins that build and turn over the extracellular matrix in vitro — reported strictly as what the cell-culture experiment measured, not as an outcome in any organism.

BPC-157: the synthetic pentadecapeptide

BPC-157 is a synthetic pentadecapeptide — a chain of fifteen amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val). The “BPC” stands for Body Protection Compound. The sequence corresponds to a partial fragment of a protein identified in gastric juice, which is why it is often described as a “gastric pentadecapeptide.” Unlike a hormone analog, BPC-157 is not built on a known receptor-ligand template; it is a defined synthetic sequence studied largely on its own terms.

The published BPC-157 literature is dominated by preclinical animal studies, many of them focused on tissue-repair and vascular endpoints. For example, one rat study measured the peptide’s modulatory effect on angiogenesis (new blood-vessel formation) during muscle and tendon healing models (Brcic et al., Journal of Physiology and Pharmacology, 2009). As with every compound in this blend, the relevant framing is what the model measured — a vascular and tissue-repair readout in rodents — rather than any claim about a result in a person.

TB-500: the actin-binding fragment

TB-500 is a synthetic heptapeptide (seven amino acids, sequence Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, often written Ac-LKKTETQ). It corresponds to the central actin-binding region of a larger, naturally occurring 43-amino-acid protein called thymosin β-4 (Tβ4) — specifically residues 17–23, the segment that carries Tβ4’s actin-binding activity. TB-500 is therefore best described as a synthetic fragment of thymosin β-4, not the full protein.

The defining molecular property of thymosin β-4, and of this fragment, is G-actin sequestration: the peptide binds monomeric (globular) actin in a one-to-one ratio and holds it in an unpolymerized pool. Cell-biology research measured Tβ4 acting as a potent regulator of actin polymerization in living cells, where the amount of peptide present shifted the balance between monomeric and filamentous actin (Sanders et al., Proceedings of the National Academy of Sciences, 1992). Separate work mapped the actin-binding site on thymosin β-4 to its role in angiogenesis assays (Philp et al., The FASEB Journal, 2003). These studies describe what the molecule does to the actin cytoskeleton in experimental systems — the mechanistic basis for why the fragment is studied at all.

KPV: the C-terminal tripeptide of α-MSH

KPV is the simplest of the four: a tripeptide of lysine, proline and valine (Lys-Pro-Val). It corresponds to the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH) — the last three residues of that hormone’s sequence. Notably, KPV lacks the core sequence that α-MSH uses to bind melanocortin receptors, so it is studied as a fragment that retains certain activities of the parent hormone while being structurally distinct from the receptor-binding portion.

The published KPV literature centers on inflammatory signaling in cell and animal models. One study measured the tripeptide’s anti-inflammatory effect in murine models of inflammatory bowel disease, where it reduced markers of intestinal inflammation (Kannengiesser et al., Inflammatory Bowel Disease, 2008). Mechanistic work in this area has associated KPV with inhibition of NF-κB, a transcription-factor pathway central to inflammatory gene expression. Again, these are measurements taken in defined research models, not statements about any effect in an individual.

Frequently asked questions

What is the KLOW blend?

KLOW is a four-component research peptide blend whose name is an acronym for its constituents: KPV, GHK-Cu (sometimes the “L” is read from the “low” of GLOW), BPC-157 and TB-500. It is a single preparation containing four chemically distinct peptides, each with its own sequence and published literature.

What is the difference between KLOW and GLOW?

GLOW combines three peptides — GHK-Cu, BPC-157 and TB-500. KLOW is GLOW with the tripeptide KPV added. KLOW therefore contains four components and GLOW contains three.

Are the four KLOW components related to each other chemically?

No. They belong to different structural families: GHK-Cu is a copper-bound tripeptide, BPC-157 is a synthetic fifteen-amino-acid peptide, TB-500 is a synthetic seven-amino-acid fragment of thymosin β-4, and KPV is a three-amino-acid fragment of α-MSH. None is derived from another.

Is TB-500 the same as thymosin β-4?

No. Thymosin β-4 is a naturally occurring 43-amino-acid protein. TB-500 is a synthetic seven-amino-acid peptide corresponding to the actin-binding region (residues 17–23) of that larger protein, so it is a fragment rather than the full molecule.

What does the “Cu” in GHK-Cu mean?

The “Cu” is the chemical symbol for copper. GHK-Cu is the glycyl-histidyl-lysine tripeptide bound to a copper(II) ion, forming a copper-peptide complex. The histidine residue gives the peptide its affinity for copper.

What is KPV derived from?

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH). It is the final three amino acids of that hormone’s sequence and lacks the melanocortin-receptor-binding core of the parent molecule.

References

1. Siméon A, et al. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences. 2000. PMID: 11045606.
2. Brcic L, et al. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology. 2009. PMID: 20388964.
3. Sanders MC, et al. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proceedings of the National Academy of Sciences of the United States of America. 1992. PMID: 1584803.
4. Philp D, et al. The actin binding site on thymosin beta4 promotes angiogenesis. The FASEB Journal. 2003. PMID: 14500546.
5. Kannengiesser K, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Disease. 2008. PMID: 18092346.

For research use only. The products and materials discussed are intended for laboratory research purposes and are not for human or veterinary use, diagnosis, or treatment. This article describes the chemical structure and published pharmacological research of a compound and does not constitute a claim of any effect in any individual.